摘要
目的使用TCGA数据库,探索DNA甲基化位点对肺腺癌的预后影响。方法使用TCGA数据库,获取肺腺癌病人癌和癌旁组织甲基化表达数据、基因表达数据及临床数据;将人群分为探索组和验证组,使用LASSO在探索人群中筛选对肺腺癌预后有影响的甲基化位点;受试者工作特征曲线用于评估甲基化位点预测效果,并进一步在验证人群中验证。结果在TCGA数据库中筛选出158个癌和癌旁组织差异表达且与所在基因mRNA表达显著相关的甲基化位点,经LASSO回归分析,cg19378330与肺腺癌预后相关。甲基化位点水平高于中位数的患者,归入高风险组,甲基化位点水平低于中位数的为低风险组。结果发现与低风险组相比,高风险组的死亡风险比低风险组增加了38%(OR=1.38,95%CI=1.16~2.69)。在探索阶段人群中其曲线下面积为0.80(95%CI=0.73~0.88),灵敏度为86.2%。验证人群中也表现出类似结果。结论甲基化位点cg19378330与肺腺癌具有较显著的关联性,且可以对肺腺癌的风险进行有效的预测。
Objective Using the TCGA database to explore the prognostic effects of DNA methylation sites on lung adenocarcinoma.Methods TCGA database was used to collecting DNA methylation data,gene expression data and clinical data of lung adenocarcinoma patients.The population were divided into the exploratory group and the validation group.The LASSO regression analysis was used to screen the methylation sites associated with the prognosis of lung adenocarcinoma in the exploratory group.Receiver operating characteristic curve was used to evaluate the prediction effect of the model,and further verified in the validation population.Results A total of 158 methylation sites with differential expression and significant correlation with the mRNA expression of the corresponding gene were screened from the TCGA database.With LASSO regression analysis,the DNA methylation sites associated with prognosis of lung adenocarcinoma were cg19378330.Those patients with levels above the median methylation site were assigned to the high-risk group,while those with levels below the median methylation site were assigned to the low-risk group.Patients death risk in the high-risk group were 38%higher than those in the low-risk group(OR=1.38,95%CI=1.16-2.69).The area under the curve was 0.80(95%CI=0.73-0.88)and the sensitivity was 86.2%in the exploratory stage population.Similar results were seen in the validation population.Conclusions The DNA methylation site cg19378330 was significantly associated with the prognosis of lung adenocarcinoma,and could effectively predict the risk of lung adenocarcinoma.
作者
刘颖
方子晗
张雅琴
王可
LIU Ying;FANG Zihan;ZHANG Yaqin;WANG Ke(Guangzhou First People's Hospital,Guangzhou 510180,China;Department of Preventive Medicine,Medical College,Hubei University of Arts and Sciences,Xiangyang 441053,China;Research Centre for Evidence-Based and Translational Medicine,Xiangyang Central Hospital,Affiliated hospital of Hubei University of Arts and Science,Xiangyang 441053,China)
出处
《广州医药》
2022年第3期112-117,共6页
Guangzhou Medical Journal
基金
湖北省教育厅科学技术研究计划青年人才项目(Q20212605)
湖北省大学生创新训练项目(S2020105109031)
湖北文理学院教师科研能力培育基金(2020kypyfy030)。
